Equity Research on Abbott Laboratories and GlaxoSmithKline plc – Drug Makers Contending With Development Costs

NEW YORK, NY--(Marketwire - Sep 27, 2012) - http://www.ShinesRooms.com has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drug Manufacturers - Major industry and are offering free analytical research on Abbott Laboratories ( NYSE : ABT ) and GlaxoSmithKline plc ( NYSE : GSK ). Register with us now to have free access to these research reports. Simply click on the link below. http://www.ShinesRooms.com/index.php?_controller=RegisterMember&_method=index

Many major drug manufacturers are struggling to grow profits at this time as development costs continue to escalate, competition remains strong and demand levels stay relatively flat. Get your free reports on Abbott Laboratories and GlaxoSmithKline plc at http://www.ShinesRooms.com/index.php?_controller=RegisterMember&_method=index. There is no commitment to join.

ShinesRooms.com is the Ultimate Trading Environment for investors. If you are considering owning Abbott Laboratories and GlaxoSmithKline plc then you should sign up for a free membership and our complimentary reports today. Over the last 5 years our returns outpaced any of the major indexes. Sign up today by clicking on the link below to find out what you are missing. http://www.ShinesRooms.com

New industry efforts to curb development costs may lead to long-term savings. A new company, Transcelerate Biopharma, is being formed with the specific aim of improving five key areas of clinical trials. Transcelerate intends to register as a non-profit and already has the support of some of the industry's leaders including Abbott Laboratories and GlaxoSmithKline plc. Abbott Laboratories report is accessible for free by registering today at http://www.ShinesRooms.com/AbbottLaboratories270912.pdf

The above efforts could bring down costs in the long-term but the short-term still remains a concern. Drug manufacturers are employing a variety of strategies to grow revenues from existing drugs to lessen dependency on getting new ones to market. GlaxoSmithKline, for example, is currently aiming to expand the label of its Synflorix in the European Union. Others are focusing more on getting their drugs into new markets where the threat of competition is lower. GlaxoSmithKline plc report is accessible for free by registering today at http://www.ShinesRooms.com/GlaxoSmithKlineplc270912.pdf

The two Drug Manufacturers - Major stocks research reports are available for free by signing up now on the link below. http://www.ShinesRooms.com

About Shinesrooms.com Shine's Rooms is the brainchild of David Shine, a 13-year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting-edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link http://www.shinesrooms.com/disclaimer.html.

View post:
Equity Research on Abbott Laboratories and GlaxoSmithKline plc - Drug Makers Contending With Development Costs